AUG 31, 2020 9:38 AM PDT

Targeting Your Inner Hedgehog to Fight Chemoresistance in Colorectal Cancer

WRITTEN BY: Jasper Cantrell

Chemoresistance is a serious problem for many cancer therapies. Solutions to this problem are harder to come by than the medicines themselves, but a team from Sapienza University in Rome may have an answer for colorectal cancer.

Colorectal cancer is known for developing chemoresistance. However, a recent study pointed to a signaling pathway, the Hedgehog-GLI pathway, as a critical player in developing that resistance. This pathway is typically involved in regulating cell differentiation in early development but has also been linked to tumor development when dysregulated. The team decided to conduct a new study to determine how the Hedgehog- GLI pathway is involved in colorectal cancer’s chemoresistance.

The study began by examining the protein GLI, the genetic regulator involved in the Hedgehog-GLI pathway, in colorectal cancer cells after treatment with the first-line chemotherapies. The drugs both activated and upregulated GLI, and increased cancer cell death - albeit alongside a small increase to growth at low doses. Using a GLI inhibitor alongside the chemotherapy drugs suppressed this growth effect and increased the chemotherapies’ anti-cancer activity. So they knew that inhibiting GLI prevented GLI dependent growth, but how did it do it?

The team knew that a particular family of transporters, ATP-binding cassettes (ABC) transporters, were often involved in drug resistance and may play a role in Hedgehog-GLI mediated chemoresistance. They identified several down-regulated members during GLI inhibition and found that GLI overexpression coincided with the ABC transporters’ overexpression as well. This effectively linked the Hedgehog-GLI pathway to ABC transporters, which are known to facilitate chemoresistance in cancers.

This study’s data supports the idea that Hedgehog-GLI mediated chemoresistance is given by GLIs activation of certain ABC-transporters. This pathway has already been the target of several therapy studies, but the team notes that so far, many have ended poorly. However, this new information will assist with future studies by providing a viable target, GLI.

The team concludes, “Indeed, our results indicate that the addition of GLI targeting drugs to CRC treatment strategies is a therapeutic option that could prevent the onset of chemoresistance.”

Sources: Nature Scientific Reports, Science in HD, Research Square

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
AUG 11, 2020
Cancer
Aspirin could accelerate cancer progression in older adults
AUG 11, 2020
Aspirin could accelerate cancer progression in older adults
Alarming research published in the Journal of the National Cancer Institute points toward the association between a ...
AUG 26, 2020
Cancer
NAP-6: A Potential Candidate for the Treatment of Breast Cancer
AUG 26, 2020
NAP-6: A Potential Candidate for the Treatment of Breast Cancer
The body is an amazing and complex system of pathways, all working together in harmony. However, cancer can quickly disr ...
SEP 22, 2020
Cardiology
Investigating the Mechanism Behind 5-Fluorouracil's Cardiotoxicity
SEP 22, 2020
Investigating the Mechanism Behind 5-Fluorouracil's Cardiotoxicity
Cancer therapies have come quite far, with several options available for many cancers. An issue that has plagued many of ...
OCT 05, 2020
Health & Medicine
Cannabis Chemotherapy Trial Shows Encouraging Phase II Results
OCT 05, 2020
Cannabis Chemotherapy Trial Shows Encouraging Phase II Results
Even with the best anti-nausea medications one in three patients receiving chemotherapy experiences vomiting, and about ...
OCT 26, 2020
Cancer
Investigating the Receptor Protein FPR1 in Brain Cancer
OCT 26, 2020
Investigating the Receptor Protein FPR1 in Brain Cancer
Amongst the more common targets for cancer therapies are cell surface receptors. These receptors are proteins – us ...
OCT 28, 2020
Cancer
Race disparities still exist among patients with lung cancer
OCT 28, 2020
Race disparities still exist among patients with lung cancer
Research published recently in the Journal of Surgical Oncology looks at the disparities in lung cancer treatment a ...
Loading Comments...